According to a recent market study published by Growth Market Reports, titled, “Global Leukocyte Reduction Filter Market is segmented into by type, by filter type, by usage, by end-use verticals and by region: Size, Share, Trends and Opportunity Analysis, 2016-2031”, the market was valued at US$ 291.9 Million in 2022 and is expected to grow at a growth rate of 5.1% by the year 2031.

Get Sample Report @ https://growthmarketreports.com/request-sample/156

Leukoreduction is the removal of leukocytes from blood components. Each leuko-reduced product has residual leukocyte counts of less than 5×106 cells per unit. Leukoreduction is performed using Leukocyte Reduction Filters (LRFs) that trap leukocytes, while allowing the desired blood product to pass through. Leukoreduction reduce adverse transfusion reactions such as febrile non-haemolytic transfusion reactions (FNHTR), alloimmunization against human leukocyte antigens (HLA) and human platelet antigens (HPA), which cause refractoriness to platelet transfusion, and transmission of infectious diseases. In addition, leukoreduction prevent the release of leukocyte metabolites, such as cytokines and histamine. These metabolites contribute to adverse reactions and increase the percentage of hemolysis in red blood cell (RBC) products.

On the basis of type, the global leukocyte reduction filter market is segregated into whole blood filtration, red blood cell filtration, platelet filtration, & plasma filtration. The whole blood filtration segment is projected to expand at a rapid pace during the forecast period as it helps in treating wider range of conditions. Whole blood filtration removes harmful substances or pathogens from whole blood, making it usable for a broader range of therapeutic applications such as sepsis, and autoimmune diseases.

On the basis of filter type, the global leukocyte reduction filter market is segregated into membrane, antibacterial, antiviral, and pocket. The antibacterial segment is expected to hold a significant share of the market during the forecast period as it helps purify blood products and reduce the risk of transfusion-related complications and infections. The filter incorporates antibacterial agents to further enhance the prevention of microbial contamination. It ensures safety and efficacy of blood components during the transfusion.

Based on the usage, the global Leukocyte Reduction Filter market is segmented into single-use and reusable. The single-use segment is expected to hold a significant share of the market during the forecast period as it maintains optimal filtration efficiency. It helps reduce the potential contamination and infection. Single-use leukocyte reduction filter is a valuable tool for improving the safety and efficacy of blood transfusions. They are widely used in hospitals and blood banks around the world and are an essential part of modern blood banking practices.

In terms of end-use verticals, the global leukocyte reduction filter market is bifurcated into hospitals, blood banks, laboratory, & others. The Laboratory segment is projected to expand at a significant pace, as large number of disease screening prior to transfusion therapy are majorly performed in the laboratories. The demand for blood transfusion diagnostic such as blood component separators, apheresis, and other consumables is high in diagnostic laboratories.

The outbreak of Coronavirus disease in 2019 (COVID-19) had a negative impact on the global Leukocyte Reduction Filter market. Professionals in blood transfusion had to cope with uncertain patterns of blood demand, lack of investments, and loss of key staff due to pandemic. The monitoring of supply and demand for adequate blood stocks to support ongoing critical needed in hospitals and separate blood transfusion centers for surgeries or major traumas was a key strategy for transfusion institutions during the pandemic. The COVID-19 pandemic led to substantial healthcare disorders due to constraints of resources, supply chain disorders, the high need to protect or cover healthcare workers, the physical distancing, and to cater to rising of demand for essential services. Many healthcare centers responded by cancelling or postponing optional surgeries.

As per Growth Market Reports by industry analyst Anuradha more, “Increasing incidence and prevalence of leukaemia and Growing demand for platelets and plasma are expected to increase the usage of leukocyte reduction filter.”

Supply chain management is an essential part of any business. A supply chain contains a series of steps to get products from their original state to the customers. Raw materials used for manufacturing leukocyte reduction filter are shipped to manufacturers to process into final products. Quality checks are performed throughout the production process by manufacturers to ensure the quality of the product.

Key Takeaways from the Study:

The players in the Global leukocyte reduction filter market include Fresenius Kabi AG (Fresenius SE & Co. KGaA); Haemonetics Corporation; Macopharma; TERUMO BCT, INC. (Terumo Corporation); Nanjing Shuangwei Biotechnology Co., Ltd.; Bıçakcılar; SB-KAWASUMI LABORATORIES, INC.; PuriBlood Medical; Nanjing Sunway Biomedical Technology Co., Ltd.; Guangzhou Daji Medical Science and Technology Co., Ltd.; Shandong Zhongbaokang Medical Implements Co., Ltd.; Mitra Industries (P) Ltd.

Report Scope:

Report Metric

Details

Market Value in 2022

US$ 291.9 Million

Market Growth Rate

5.1%

Historical Data

2016 & 2031

Base Year

2022

Forecast Period

2023 – 2031

Units Considered

Value (US$ Million)

Market Segments

By Type, By Filter Type, By Usage, By End-Use Verticals

Key Companies Profiled

Fresenius Kabi AG (Fresenius SE & Co. KGaA); Haemonetics Corporation; Macopharma; TERUMO BCT, INC. (Terumo Corporation); Nanjing Shuangwei Biotechnology Co., Ltd.; Bıçakcılar; SB-KAWASUMI LABORATORIES, INC.; PuriBlood Medical; Nanjing Sunway Biomedical Technology Co., Ltd.; Guangzhou Daji Medical Science and Technology Co., Ltd.; Shandong Zhongbaokang Medical Implements Co., Ltd.; Mitra Industries (P) Ltd.

Customization Scope

Report customization available on request

Pricing and Purchase Options

Avail of tailor-made purchase options to meet your research requirements.

Target Audience:

  • Supply-side: Manufacturer and distributors.

  • Demand Side: Hospital, Blood Banks, laboratory

  • Regulatory Side: Approved regulatory bodies.

  • Associations and Industry Bodies: American Association of Blood Banks (AABB), National Regulatory Authorities (NRA), Food and Drug Administration (FDA), World Health Organization (WHO) , Public Health Service (PHS), Center for Biologics Evaluation and Research (CBER), International Organization for Standardization (ISO), Department of Health and Human Services (DHHS), Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), & Health Resources and Services Administration (HRSA).